Idiopathic Pulmonary Fibrosis Therapeutics Market Size in the 7MM was ~USD 3,300 million in 2023, estimated DelveInsight

DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology and Market Forecast-2034" report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Idiopathic Pulmonary Fibrosis Market by downloading the comprehensive report from DelveInsight @ Idiopathic Pulmonary Fibrosis Treatment Market Size [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Idiopathic Pulmonary Fibrosis Market Report

* In December 2024:- Boehringer Ingelheim- This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older. If they already take nintedanib or pirfenidone for their IPF, they can continue treatment throughout the study. The purpose of this study is to find out whether a medicine called BI 1015550 helps people with IPF.
* In December 2024:- Vicore Pharma AB- The trial will include participants who are on stable licensed IPF therapy or who are currently not treated with a licensed IPF therapy. The latter group will include participants intolerant or not responsive to licensed IPF therapies, participants ineligible to receive these therapies, and participants who have voluntarily declined to receive a licensed IPF therapy after being fully informed of the potential benefits and risks of such therapy. Due to the potential risk of drug-drug interactions (DDIs), concomitant treatment with pirfenidone is not allowed in this trial. Participants who are not on antifibrotic therapy at study start may initiate such treatment during the study.
* It is estimated that the Idiopathic Pulmonary Fibrosis treatment market will experience significant changes during the forecast period of 2024-2034, owing to the launch of new therapies that are in clinical development.
* As per DelveInsight analysis in 2023, there were nearly 192 thousand cases of diagnosed prevalent cases of IPF in the 7MM. Among which the US accounted for the highest around 94 thousand cases alone. These cases are anticipated to follow the same trend and rise gradually throughout the 2024-2034 period.
* DelveInsight's analysis shows that males had a higher prevalence of diagnosed IPF cases than females in 2023. In the US, approximately 53 thousand males and 41 thousand females were affected by the disease. These figures suggest a significant gender disparity in the prevalence of idiopathic pulmonary fibrosis.
* DelveInsight's 2023 analysis in Japan segmented IPF cases by age, revealing the highest prevalence in the 80+ age group, with nearly 26 thousand cases.
* In 2023, the EU4 and the UK had nearly 78 thousand diagnosed prevalent cases of IPF, with Germany accounting for the highest number of cases in the region.
* Our secondary analysis found that in 2023, the EU4 and the UK reported approximately 39 thousand diagnosed cases of moderate IPF, while only about 16 thousand cases were classified as severe IPF.
* The leading Idiopathic Pulmonary Fibrosis Companies such as FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
* Promising Idiopathic Pulmonary Fibrosis Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809 , and others.

Gain a competitive edge in the Idiopathic Pulmonary Fibrosis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Idiopathic Pulmonary Fibrosis Treatment Drugs [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation in the 7MM

* Total Idiopathic Pulmonary Fibrosis Diagnosed Prevalent Cases
* Idiopathic Pulmonary Fibrosis Gender-specific Diagnosed Prevalent Cases
* Idiopathic Pulmonary Fibrosis Age-specific Diagnosed Prevalent Cases
* Idiopathic Pulmonary Fibrosis Severity-specific Diagnosed Prevalent Cases

Idiopathic Pulmonary Fibrosis Market Insights

IPF is characterized by lung scarring, which progressively impairs breathing. It is believed that damage to the alveolar epithelium and abnormal wound healing play significant roles in the disease's progression. The treatment of IPF encompasses both pharmacological and non-pharmacological strategies aimed at managing symptoms and slowing disease progression. "At present, two medications are authorized for managing IPF: OFEV and ESBRIET. These agents, classified as anti-fibrotics, have demonstrated efficacy in clinical trials by decelerating lung fibrosis or scarring. Pirfenidone, a modified pyridine compound, possesses properties that are anti-fibrotic, anti-inflammatory, and antioxidant, contributing to its therapeutic effects in IPF."

Discover key developments and opportunities in the Idiopathic Pulmonary Fibrosis Market. Click here to learn more from DelveInsight's latest report @ Idiopathic Pulmonary Fibrosis Market Size [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Idiopathic Pulmonary Fibrosis Emerging Therapies Profile

* BI 1015550: Boehringer Ingelheim
* Tyvaso (treprostinil): United Therapeutics
* Garadacimab: CSL Behring

Idiopathic Pulmonary Fibrosis Marketed Drugs

* OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH

Idiopathic Pulmonary Fibrosis Market Outlook

There are two antifibrotic agents approved for use in idiopathic pulmonary fibrosis. These are Pirfenidone and Nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies have also decreased exacerbations of idiopathic pulmonary fibrosis with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with Nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort.

Download DelveInsight's Idiopathic Pulmonary Fibrosis Market report today and stay ahead in this rapidly evolving field. @ Idiopathic Pulmonary Fibrosis Clinical Trials [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Idiopathic Pulmonary Fibrosis Market Report

* Coverage- 7MM
* Idiopathic Pulmonary Fibrosis Companies- FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
* Idiopathic Pulmonary Fibrosis Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, and others.
* Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Idiopathic Pulmonary Fibrosis Unmet Needs, KOL's views, Analyst's views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis Market Trends @ Idiopathic Pulmonary Fibrosis Market Trends [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1 Key Insights

2 Report Introduction

3 Idiopathic Pulmonary Fibrosis (IPF) Market Overview at a Glance

4 Epidemiology and Market Forecast Methodology

5 Key Events

6 Executive Summary of Idiopathic Pulmonary Fibrosis (IPF)

7 Disease Background and Overview of IPF

8 Epidemiology and Patient Population of IPF

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs

12 IPF: Seven Major Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet needs

16 Market Access and Reimbursement

17 Appendix

18 Report Methodology

19 DelveInsight Capabilities

20 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=idiopathic-pulmonary-fibrosis-therapeutics-market-size-in-the-7mm-was-usd-3300-million-in-2023-estimated-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.